共 79 条
[1]
Neelapu SS(2017)Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma N Engl J Med 377 2531-2544
[2]
Locke FL(2020)Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study Lancet 396 839-852
[3]
Bartlett NL(2019)Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma N Engl J Med 380 45-56
[4]
Abramson JS(2019)Toxicities of CD19 CAR-T cell immunotherapy Am J Hematol 94 S42-S49
[5]
Palomba ML(2022)Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US J Med Econ 25 541-551
[6]
Gordon LI(2019)Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial Lancet Oncol 20 31-42
[7]
Schuster SJ(2021)Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial Blood Adv 5 1695-1705
[8]
Bishop MR(2018)Grading of neurotoxicity in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) receiving tisagenlecleucel treatment in the JULIET study Blood 132 4183-2176
[9]
Tam CS(2018)Consensus grading of cytokine release syndrome (CRS) in adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) treated with tisagenlecleucel on the JULIET Study Blood 132 4190-374
[10]
Hirayama AV(2021)Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials Leuk Lymphoma 62 2169-2119